Mauna Kea Technologies Reports Fourth Quarter and Full Year 2021 Sales
Global 2021 sales grew +18% year-over-year to €7.7M
Mauna Kea Technologies announced fourth quarter and full year 2021 sales.
Total Sales for the Full Year 2021 increased €1.17 million, +18% year-over-year, to €7.70 million
- Systems sales at €3.19 million, +24% year-over-year
- Consumables sales at €3.20 million, +13% year-over-year
- Services sales at €1.30 million, +17% year-over-year
Total Sales for the Fourth Quarter of 2021 increased €0.23 million, +10% year-over-year, to €2.61 million
- Systems sales at €1.23 million, +8% year-over-year
- Consumables sales at €0.92 million, -5% year-over-year
- Services sales at €0.46 million, +70% year-over-year
Total Sales for the Fourth Quarter of 2021 increased €0.23 million, +10% year-over-year, to €2.61 million
“For the full year, global sales increased +18% year-over-year despite the unpredictable effects of the COVID-19 pandemic on the healthcare industry. Our strong installed base of users in the U.S. has enabled us to achieve +17% sales growth in this region even with pandemic-associated delays in elective procedures and capital sales. In Asia, which has operated in full isolation, we saw a modest decline of -11% in sales. In Europe, our focus on pancreatic cysts and food allergy applications has yielded a +66% growth in sales year-over-year, nearly returning to pre-pandemic levels,” said Nicolas Bouvier, interim Chief Executive Officer of Mauna Kea Technologies. “The efforts to establish a core base of committed U.S. users over the past three years, combined with our strategic repositioning and associated operating plan with optimized resources, are giving us much better visibility. We’re looking forward to executing our new strategic plan and regularly updating our investors on our progress.”
